. We have previously communicated the results of a double-blind cross-over trial of clonazepam in 30 patients whose epilepsy was poorly controlled (Nanda et al., 1976) . The trial extended over a period of nine weeks and we now report the results during the following year of the treatment in those patients who benefited. In addition, we report the effect of clonazepam Blood samples were taken before and after clonazepam treatment for measurement of serum concentrations of anticonvulsants, and for haematological examination and estimations of liver function, blood urea, and electrolytes. Measurements of phenytoin, phenobarbitone, and primidone were performed by a gas chromatographic technique (Goudie and Burnett, 1973 Eleven patients in the double-blind trial had focal attacks and tonic-clonic seizures. There was a 500%
reduction in tonic-clonic seizures during the trial in only four patients, and after a year only two of these continued to show improvement. The overall changes in dosage ofclonazepam in the patients who continued to take the drug after the double-blind trial are shown in Table 2 . For the patients in the open trial, the effect of clonazepam on seizure frequency after one year is shown in Table 3 . Seven patients with myoclonic epilepsy and tonic-clonic seizures ceased to have attacks, and have remained free of attacks for a year. Of seven patients with photosensitive epilepsy, six showed abolition of seizures and the seventh marked improvement.
Clonazepam was less effective in the six patients (Fig. 1) . Serum concentrations ofclonazepam in these patients ranged from 0.3 to 104 nmol/l (Fig. 2) . In the open trial, plasma clonazepam concentrations in patients whose epilepsy was well controlled on 2-12 mg of clonazepam daily ranged from 17 to 330 nmol/l (Fig. 3) . Treatment with other anticonvulsants appeared to decrease serum concentrations of clonazepam. A graph of phenobarbitone concentrations against clonazepam concentrations has a negative slope with a significant negative correlation (P<0.01) (Fig. 4) suggesting that phenobarbitone depresses clonazepam concentrations in blood. No biochemical or haematological abnormalities were noted during treatment with clonazepam.
Discussion
The results of these trials indicate that clonazepam is very effective in the treatment of generalised epilepsy with myoclonic jerks alone or with tonic-clonic seizures. This result is of considerable importance as this form of epilepsy has previously been very difficult to treat (Van Woert and Sethy, 1975) . The drug was also found to be particularly effective in photosensitive epilepsy. The value of the drug in epilepsy with associated myoclonus has been demonstrated in open trials but the numbers of patients have been small, two trials only having five patients each with this condition (Goldberg and Dorman, 1976; Huang et al., 1974) . In a double-blind trial, Edwards and Eadie (1973) have shown that the drug is of value as a wide spectrum anticonvulsant, but few of their patients had myoclonic epilepsy, and there is no indication that any had photosensitive epilepsy. Our results for patients with atypical absences, tonic-clonic epilepsy, and temporal lobe epilepsy also indicate that clonazepam is sometimes of value in these forms ofepilepsy.
In focal epilepsy our results in the patients in the double-blind trial suggested that the drug was of little value. This is contrary to the experiences in other centres (Huang et al., 1973; Scollo-Lavizzari et al., 1974) , and it is possible that the daily dosage of 3 mg of clonazepam in our trial was insufficient for control of this type ofepilepsy as a higher dosage was reported as being necessary in temporal lobe epilepsy (Huang et al., 1973) . More satisfactory results were obtained in our open trial when the clonazepam dosage was increased (up to 10 mg daily) in the focal epilepsies.
Serum concentrations of clonazepam in our patients ranged from 0.3-330 nmol/l on a daily dose of 2-12 mg. It has previously been reported (Naestoft et al., 1973; Dreifuss et al., 1975) serum concentrations ranged from 40-240 nmol/l. We found that patients in the double-blind trial who showed clonazepam concentrations below 40 nmol/l were those who responded poorly to the drug. Our results suggest that treatment with other anticonvulsants, particularly phenobarbitone or primidone (which metabolises to phenobarbitone), lowers serum concentrations of clonazepam. In particular, all of the patients with focal epilepsy treated with phenobarbitone and clonazepam showed high serum concentrations ofphenobarbitone and low concentrations of clonazepam in keeping with this suggestion.
Conflicting reports have suggested previously that clonazepam may either raise or depress phenytoin or phenobarbitone serum concentrations (Edwards and Eadie, 1973; Daurella, 1974; Hara et al., 1976) , but it has also been concluded (Huang et al., 1973) 
